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Abstract
Recent studies have shown that HDAC inhibitors act synergistically with camptothecin deriv-
atives in combination therapies. To exploit this synergy, new hybrid molecules targeting
simultaneously topoisomerase I and HDAC were designed. In particular, a selected multiva-
lent agent containing a camptothecin and a SAHA-like template showed a broad spectrum
of antiproliferative activity, with IC50 values in the nanomolar range. Preliminary in vivo
results indicated a strong antitumor activity on human mesothelioma primary cell line
MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.
Introduction
Over the last two decades, drug discovery has been primarily focused on the development of
single-target drugs with high potency and selectivity. However, single target agents can per-
form excellently during the treatment of diseases with linear pathways. Multi-factorial diseases
with complex signalling networks, such as cancer, are robust and can be efficiently eradicated
only by the simultaneous attack of multiple targets.
A well-established strategy for anticancer therapy is the rational design of drug combina-
tions aimed at achieving synergistic effects and overcoming drug resistance. However, the
combination of agents that exhibit synergistic interaction in cell culture can be less effective
than expected. This is mainly due to differential pharmacokinetic behaviour of each drug and
to the difficulty to afford optimal concentrations for the required time [1]. Other shortcomings
of drug combinations are unpredictable drug-drug interactions and possible enhancement of
adverse effects. To overcome these limitations, an increase of interest has been made recently
in hybrid bifunctional agents designed to inhibit simultaneously multiple cellular targets rele-
vant to tumour growth/survival [2–5]. The benefits of drugs with multiple targets could be (a)
improvement of the efficacy by exploiting synergistic interactions; (b) enhancement of the
selectivity resulting in a better tolerability; (c) modulation of drug resistance. Additionally,
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multivalent molecules are expected to provide pharmacokinetic and pharmacodynamic advan-
tages over the separate administration of the two drug components [4, 5].
One attractive pathway for tumour growth inhibition is the protein acetylation state modu-
lation by histone deacetylases (HDACs). To date, 18 human HDACs have been identified and
grouped into four classes on the basis of their homology with yeast proteins [6]. Class I
HDACs (HDAC1, 2, 3, and 8) share high homology with the yeast transcriptional regulator
RPD3; class II HDACs are closely related to HDAC1 (HDAC4, 5, 6, 7, 9, and 10); class III
HDACs, also called sirtuins, are homologous with Sir2 (SIRT1, 2, 3, 4, 5, 6, and 7), and class IV
HDAC (HDAC11) is homologous with class I and II enzymes. HDAC inhibitors have already
surpassed the clinical trial stage, culminating with the approval of Vorinostat, originally
known as SAHA (suberoylanilide hydroxamic acid), romidepsin (FK228), panobinostat (LBH-
589), and belinostat (formerly PXD-101) [6, 7] (Fig 1).
Another class of therapeutic agents acting at a nuclear level are topoisomerase I inhibitors
[8, 9]. Topoisomerases relieve the torsional stress associated with the separation of DNA
strands during transcription and DNA replication. Eukaryotic Topoisomerase I (Top1) is a
Type IB enzyme that nicks and rejoins only one strand of duplex DNA, and it is critically
important for maintaining genome integrity [10]. Many small molecule inhibitors of Top1
have proven clinically effective, the most potent being the camptothecin (CPT) derivatives [11,
12] (Fig 1).
Two semisynthetic camptothecins have been approved by US FDA for cancer chemother-
apy: Irinotecan (CPT-11) and Topotecan. Belotecan (Camtobell) has been approved in South
Korea for treatment of NSCLC (Fig 1). Other derivatives are in different stages of clinical
development, such as Lipotecan [13] and BAY 56–3722 [14], together with a number of mac-
romolecular delivery agents and supramolecular assemblies [15].
The cancer-promoting mechanism of HDAC involves transcriptional silencing of tumor
suppressors via deacetylation of nucleosomes containing tumor suppressor genes. HDAC inhi-
bition has been reported to affect cancer cells mainly by a global relaxation of chromatin struc-
ture, which contributes to a recovered cell response to chemotherapeutic agents targeting
DNA [16]. In this respect, there is a lot of evidence showing that co-treatment with HDAC
inhibitors and camptothecin derivatives (such as Topotecan, Irinotecan) synergistically block
cell proliferation [17–24]. We decided to exploit this synergistic effects by designing hybrid
inhibitors which could, in principle, interact with both targets. In particular, we chose to incor-
porate into a prototypical HDACi pharmacophore a properly substituted CPT. Classical
medicinal chemistry approaches coupled with computational analysis and biological evalua-
tion led to the definition of key molecular insights for dual inhibition.
Materials and methods
Chemistry
General information. All reagents and solvents were reagent grade or were purified by
standard methods before use. Melting points were determined in open capillaries and are
uncorrected. NMR spectra were recorded in CDCl3 (where not otherwise stated) at 300 MHz.
Chemical shifts (δ values) and coupling constants (J values) are given in ppm and Hz, respec-
tively. Solvents were routinely distilled prior to use; anhydrous tetrahydrofuran (THF) and
ether (Et2O) were obtained by distillation from sodium-benzophenone ketyl; dry methyle-
nechloride was obtained by distillation from phosphorus pentoxide. All reactions requiring
anhydrous conditions were performed under a positive nitrogen flow, and all glassware were
oven dried and/or flame dried. Isolation and purification of the compounds were performed
by flash column chromatography on silica gel 60 (230–400 mesh). Analytical thin-layer
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chromatography (TLC) was conducted on Fluka TLC plates (silica gel 60 F254, aluminum
foil). Analyses indicated by the symbols of the elements or functions were within ±0.4% of the
theoretical values. Compounds 2a [25], 1a, 2b, 2c, [3], 5 [26], 7-formylcamptothecin and
10-hydroxy-7-formylcamptothecin (1b) [27] were prepared according to literature
procedures.
Synthesis of compounds 3a-d, 10. 7-(camptothecin-7-ylmethyleneaminooxy)-hepta-
noic acid (2c). To a solution of 1a (200 mg, 0.47 mmol) in acetic acid (15 ml) with 7-aminoox-
yheptanoic acid hydrobromide (250 mg, 1.04 mmol) was added and the mixture heated 3 h at
80 ˚C. The solvent was evaporated and the residue was purified by flash chromatography with
CH2Cl2:CH3OH 93:7 to give 171 mg (70%) of compound 2c. mp:124–125 ˚C.
1H-NMR (300
MHz, CDCl3)δ: 10.50 (1H, brs); 8.84 (1H, s); 8.09 (1H, d, J = 8.5 Hz); 8.01 (1H, d, J = 8.5 Hz);
7.98 (1H, s); 7.69 (1H, dd, J = 8.5, 8.5 Hz); 7.58 (1H, s); 7.53 (1H, dd, J = 8.5, 8.5 Hz); 5.70–5.60
(1H, m); 5.28–5.15 (3H, m); 4.34 (2H, t, J = 6.3 Hz); 2.32 (2H, t, J = 6.9 Hz); 1.91–1.77 (4H, m);
1.71–1.57 (2H, m); 1.51–1.35 (4H, m); 0.89 (3H, t, J = 7.1 Hz). Anal. calcd for C28H29N3O7:
C,64.73; H, 5.63; N, 8.09; Found: C, 64.65; H, 5.61; N, 8.10.
Camptothecin-7-yl(methyleneaminooxy)-acetic acid hydroxyamide (3a). To a solution
of 2a (50 mg, 0.11 mmol) in dry DMF (1 mL), DCC (35 mg, 0.17 mmol), and N-
Fig 1. Structures of representative HDAC and topoisomerase I inhibitors.
https://doi.org/10.1371/journal.pone.0205018.g001
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hydroxysuccinimide (20 mg, 0.17 mmol) were added under nitrogen atmosphere. The mixture
was stirred 48 h at rt, then DCC (12 mg 0.06 mmol) and N-hydroxysuccinimide (7 mg, 0.06
mmol) were added. The reaction was stirred 24 h at rt, then hydroxylamine hydrochloride (23
mg, 0.33 mmol) and TEA (44 μl, 0.33 mmol) were added and stirring was continued for 24 h
at room temperature. The solvent was evaporated and the crude was purified by flash chroma-
tography with CH2Cl2:CH3OH from 195:5 to 190:10 to give 5 mg of product (10%). mp: 169
˚C. 1H-NMR (300 MHz, DMSO-d6) δ: 10.82 (1H, brs); 9.37 (1H, s); 9.00 (1H, brs); 8.62 (1H, d,
J = 8.5 Hz); 8.24 (1H, d, J = 8.5 Hz); 7.94 (1H, dd, J = 8.5, 8.5 Hz); 7.80 (1H, dd, J = 8.5, 8.5 Hz);
7.37 (1H, s); 6.55 (1H, s); 5.44 (2H, s); 5.34 (2H, s); 4.78 (2H, s); 1.99–1.77 (2H, m); 0.89 (3H, t,
J = 7.0 Hz). Anal. calcd for C23H20N4O7: C,59.48; H, 3.34; N, 12.06; Found: C, 59.63; H, 3.35;
N, 12.04.
6-(camptothecin-7-ylmethyleneaminooxy)-hexanoic acid hydroxyamide (3b). To a solu-
tion of 2b (350 mg, 0.69 mmol) in dry DMF (6 ml), WSC (172 mg, 0.9 mmol) and HOBt (112
mg, 0.83 mmol) were added under nitrogen atmosphere. The mixture was stirred 3 h at rt.
cooled to 0 ˚C, and hydroxylamine hydrochloride (240 mg, 3.45 mmol) and TEA (0.48 ml,
3.45 mmol) were added. The reaction was stirred 1 h at room temperature. The solvent was
evaporated and the residue was purified by flash chromatography with CH2Cl2:CH3OH 91: 9
to give 220 mg of product (61%). mp: 158–159˚C. 1H-NMR (300 MHz, DMSO-d6) δ: 10.36
(1H, s); 9.33 (1H, s); 8.68 (1H, s); 8.60 (1H, d, J = 8.3 Hz); 8.21 (1H, d, J = 8.3 Hz); 7.91 (1H,
dd, J = 8.3, 8.3 Hz); 7.76 (1H, dd, J = 8.3, 8.3 Hz); 7.36 (1H, s); 6.55 (1H, s); 5.44 (1H, s); 5.32
(1H, s); 4.35 (2H, t, J = 6.5 Hz); 2.00 (2H, t, J = 7.3 Hz); 1.94–1.75 (4H, m); 1.65–1.52 (2H, m);
1.51–1.38 (2H, m); 0.89 (3H, t, J = 7.0 Hz). Anal. calcd for C27H28N4O7: C,62.30; H, 5.42; N,
10.76; Found: C, 62.24; H, 5.43; N, 10.74.
7-(camptothecin-7-ylmethyleneaminooxy)-heptanoic acid hydroxyamide (3c). To a
solution of 2c (150 mg, 0.29 mmol) in dry DMF (2.5 ml), WSC (72 mg, 0.38 mmol) and HOBt
(46 mg, 0.35 mmol) were added under nitrogen atmosphere. The mixture was stirred over-
night at room temperature. The reaction was cooled to 0 ˚C and hydroxylamine hydrochloride
(101 mg, 1.45 mmol), TEA (0.2 mL, 1.45 mmol) were added. The mixture was stirred 1 h at rt.
The solvent was evaporated and the residue purified by flash chromatography with CH2Cl2:
CH3OH 91:9 to give 70 mg of product (45%). mp: 164–165˚C.
1H-NMR (300 MHz, DMSO-
d6) δ: 10.33 (1H, s); 9.31 (1H, s); 8.65 (1H, s); 8.58 (1H, d, J = 8.5 Hz); 8.21 (1H, d, J = 8.5 Hz);
7.90 (1H, dd, J = 8.5, 8.5 Hz); 7.75 (1H, dd, J = 8.5, 8.5 Hz); 7.35 (1H, s); 6.53 (1H, s); 5.43 (2H,
s); 5.30 (2H, s); 4.41–4.27 (2H, m); 2.56–2.38 (2H, m); 2.03–1.68 (4H, m); 1.64–1.23 (6H, m);
0.90 (3H, t, J = 7.0 Hz). Anal. calcd for C28H30N4O7: C,62.91; H, 5.66; N, 10.48; Found: C,
62.98; H, 5.64; N, 10.50.
6-(10-hydroxycamptothecin-7-ylmethyleneaminooxy)-hexanoic acid hydroxyamide
(3d). To a solution of 2d (287 mg, 0.56 mmol) in dry DMF (20 ml), WSC (140 mg, 0.73 mmol)
and HOBt (140 mg, 0.73 mmol) were added. The mixture was cooled to 0 ˚C and hydroxyl-
amine hydrochloride (82 mg, 1.18 mmol) and TEA (111 μl, 1.18 mmol) were added. The reac-
tion was stirred 8 h at room temperature, the solvent was evaporated and the residue was
diluted with water (40 mL). The resulting solid was filtered to obtain 220 mg of product (73%).
mp: 202–203 ˚C. 1H-NMR (300 MHz, DMSO-d6) δ: 10.49 (1H, brs); 10.36 (1H, s); 9.02 (1H, s);
8.66 (1H, brs); 8.06 (1H, d, J = 9.2 Hz); 7.72 (1H, d, J = 1.8 Hz); 7.47 (1H, dd, J = 1.8, 9.2 Hz);
7.26 (1H, s); 6.50 (1H, s); 5.41 (2H, s); 5.27 (2H, s); 4.33 (2H, t, J = 5.8 Hz); 2.04–1.93 (2H, m);
1.92–1.72 (4H, m); 1.66–1.52 (2H, m); 1.51–1.35 (2H, m); 0.89 (3H, t, J = 7.0 Hz). Anal. calcd
for C27H28N4O8: C,60.44; H, 5.26; N, 10.44; Found: C, 60.55; H, 5.27; N, 10.41.
2-(6-aminohexyloxy)-isoindole-1,3-dione) trifluoroacetate (6). To a solution of com-
pound 5 (835 mg, 2.3 mmol) in CH2Cl2 (5 mL) trifluoroacetic acid (2 mL) and was added and
the mixture was stirred 40 min at room temperature. Trifluoroacetic acid and solvent were
Hybrid top I and HDAC inhibitors as dual anticancer agents
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removed by evaporation under vacuo and the residue was grounded with ethyl ether, to give
810 mg (94%) of product. mp:99 ˚C. 1H-NMR (300 MHz, DMSO-d6) δ: 7.89–7.51 (4H, m);
4.13 (2H, t, J = 6.4 Hz); 2.86–2.72 (2H, m); 1.73–1.29 (8H, m).
N-[6-(1,3-dioxo-1,3-dihydro-isoindol-2-yloxy)-hexyl]-2-tritylsulfanylacetamide (7). To
a solution of 6 (300 mg, 0.80 mmol) in CH2Cl2 (3 ml), tritylsulfonylacetic acid (261 mg, 0.78
mmol), DMAP (5 mg, 0.04 mmol), TEA (167 μl, 1.2 mmol), and WSC (199 mg, 1.04 mmol)
were added under nitrogen atmosphere. The mixture was stirred 1.5 h at room temperature.
After dilution with dichloromethane, the mixture was washed with brine, dried and evapo-
rated. Purification by flash chromatography with hexane:EtOAc 6:4, gave 238 mg (53%) of
product. mp: 133 ˚C. 1H-NMR (300 MHz, DMSO-d6) δ: 7.88–7.70 (4H, m); 7.48–7.17 (15H,
m); 6.06 (1H, brs); 4.20 (2H, t, J = 6.4 Hz); 3.14 (2H, s); 3.02–2.91 (2H, m); 1.85–1.68 (2H, m);
1.56–1.44 (2H, m); 1.43–1.23 (4H, m). Anal. calcd for C35H34N2O4S: C,72.64; H, 5.92; N, 4.84;
Found: C, 72.48; H, 5.93; N, 4.85.
N-(6-Aminooxyhexyl)-2-tritylsulfanyl-acetamide (8). To a solution of 7 (94 mg, 0.16
mmol) in methanol (2 ml), NH2NH2.H2O (25 μL, 0.48 mmol) was added and the solution was
heated to reflux for 1h. After evaporation of the solvent, the residue was diluted with ethyl ace-
tate. The solid was filtered and the solvent evaporated under reduced pressure. Purification by
flash chromatography with hexane:EtOAc 2:1 gave 60 mg of an oil (83%). 1H-NMR (CDCl3) δ:
7.48–7.12 (15H, m); 6.01 (1H, brs); 5.35 (1H, brs); 3.65 (2H, t, J = 6.7 Hz); 3.14 (2H, s); 2.99–
2.89 (2H, m); 1.44–1.08 (8H, m). Anal. calcd for C27H32N2O2S: C,72.29; H, 7.19; N, 6.24;
Found: C, 72.09; H, 7.20; N, 6.23.
N-[6-(camptothecin-7-ylmethyleneaminooxy)-hexyl]-2-tritylsulfanylacetamide (9). To
a solution of 7-formylcamptothecin (25 mg, 0.07 mmol) in ethanol (2 mL) N-(6-aminooxy-
hexyl)-2-tritylsulfanylacetamide (8) (25 mg, 0.11 mmol) was added and the mixture was heated
5h to reflux. The solvent was evaporated and the crude was purified by chromatography with
CH2Cl2:CH3OH 98:2 to obtain 51 mg of a yellow solid (91%). mp: 108 ˚C.
1H-NMR (300
MHz, DMSO-d6) δ: 9.32 (1H, s); 8.59 (1H, d, J = 8.5 Hz); 8.22 (1H, dd, J = 8.5, 8.5 Hz); 7.90–
7.69 (2H, m); 7.40–7.15 (16H, m); 6.56 (1H, s); 5.42 (2H, s); 5.30 (2H, s); 4.34 (2H, t, J = 6.4
Hz); 3.02–2.89 (2H, m); 2.75 (2H, s); 1.94–1.69 (4H, m); 1.49–1.07 (6H, m); 0.89 (3H, t, J = 7.0
Hz). Anal. calcd for C48H46N4O6S: C,71.44; H, 5.75; N, 6.94; Found: C, 71.38; H, 5.73; N, 6.95.
N-[camptothecin-7-yl-(methyleneaminooxy)-hexyl]-2-mercaptoacetamide (10). To a
solution of 9 (63 mg, 0.08 mmol) in CH2Cl2 (2.6 mL) trifluoroacetic acid (78 μl, 1.02 mmol)
and triethylsilane (30 μl, 0.19 mmol) were added. The solution was stirred 2.5 h at room tem-
perature, the solvent was evaporated and the residue was purified by flash chromatography
with CH2Cl2:CH3OH to give 36 mg of compound 10 (80%). mp:120 ˚C.
1H-NMR (300 MHz,
DMSO-d6) δ: 9.32 (1H, s); 8.60 (1H, d, J = 8.5 Hz); 8.20 (1H, d, J = 8.1 Hz); 7.96 (1H, t, J = 5.5
Hz); 7.92–7.85 (1H, m); 7.79–7.70 (1H, m); 7.33 (1H, s); 6.53 (1H, s); 5.47–5.24 (4H, m); 4.34
(2H, t, J = 6.4 Hz); 3.10–2.99 (4H, m); 1.95–1.68 (4H, m); 1.51–1.29 (6H, m); 0.87 (3H, t,
J = 7.3 Hz). Anal. calcd for C29H32N4O6S: C,61.69; H, 5.71; N, 9.92; Found: C, 61.75; H, 5.72;
N, 9.94.
Cell lines
Human primary epithelioid MM288, MM317, MM404, MM473, MM473-Luc; biphasic
MM487 and MM491; sarcomatoid MM432 and MM472 mesothelioma cell lines (all from our
cell bank collection).
Human K562 erythromyeloblastoid leukemia (ATCC # CCL-243), ARH-77 plasma leuke-
mia (ATCC # CRL-1621), NB4 acute promyelocytic leukemia (ATCC # ACC-207), THP1 and
MV4-11 monocytic leukemia (ATCC # TIB-202, CRL-9591), Jurkat acute T-cell leukemia
Hybrid top I and HDAC inhibitors as dual anticancer agents
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(ECACC # 90112119), U937 histiocytic lymphoma (ATCC # CRL-1593), RAJI, DG-75, and
RAMOS Burkitt lymphoma (DSMZ # ACC-319, ACC-83, ACC-603); MAVER, MINO, REC-1
(DSMZ # ACC-717, ACC-687, ACC-584), JECO-1, Z-138 (ATCC # CRL-3006, CRL-3001)
mantle cell lymphoma; KM-H2 and L-428 Hodgkin lymphoma (DSMZ # ACC-8, ACC-197),
OCI-LY3 and U-2932 diffuse large B-cell lymphoma (DSMZ # ACC-731, ACC-633), RPMI-
8226 and NCI-H929 multiple myeloma (ATCC # CCL-155, CRL-9068).
Human NCI-H460 NSCLC (ATCC # HTB-177), Capan-1 pancreatic carcinoma (ATCC #
HTB-79), A431 epidermoid carcinoma (ATCC # CRL-1555), HeLa cervix carcinoma (ATCC #
CCL-2), A2780 and A2780-Dx multidrug-resistant ovarian carcinoma (ECACC # 93112519,
93112520), HT29 colorectal carcinoma (ECACC # 91072201), HepG2 hepatocellular carci-
noma (ATCC # HB-8065), DU145 prostate carcinoma (ATCC # HTB-81).
Cell cultures
All primary mesothelioma cell lines (MM288, MM317, MM404, MM473, MM487, MM491,
MM432, MM472) were cultured in F-10 Nutrient Mixture medium supplemented with 10%
Foetal Bovine Serum (FBS), 2 mM L-glutamine and gentamicin sulfate. MM473-Luc cells were
cultured in Ham’s F-10 Nutrient Mixture supplemented with 10% FBS, 2 mM L-glutamine,
and G418 antibiotic. A2780, A2780-Dx, ARH-77, DG-75, Jurkat, KM-H2, HeLa, L-428, NB4,
NCI-H60, U937, RAJI, REC-1, RPMI-8226, and U-2932 cells were cultured in RPMI-1640
medium supplemented with 10% FBS, 2 mM L-glutamine and gentamicin sulfate. JECO-1,
MAVER-2, MINO, OCI-LY3 and RAMOS cells were cultured in RPMI-1640 medium supple-
mented with 20% FBS, 2 mM L-glutamine and gentamicin sulfate. H929 and THP1 cells were
cultured in RPMI-1640 medium supplemented with 10% FBS, 0.05 mM mercaptoethanol, L-
glutamine and gentamicin sulfate. K562, MV4-11, Z-138 cells were cultured in IMDM
medium supplemented with 10% FBS, L-glutamine and gentamicin sulfate. Capan-1 cells were
cultured in IMDM medium supplemented with 10% FBS, 2 mM L-glutamine and gentamicin
sulfate. A431, DU145, and HepG2 cells were cultured in EMEM medium supplemented with
10% FBS, 2 mM L-glutamine and gentamicin sulfate. HT29 cells were cultured in McCoy’s
medium supplemented with 10% FBS, 2 mM L-glutamine and gentamicin sulfate.
Cells were maintained in an incubator at 37˚C with saturated humidity and an atmosphere
of 95% air and 5% CO2, and were sub-cultured every 2–3 days.
Cytotoxicity assay
Human tumor cells were seeded in 96-well cell culture plastic plates, allowed to attach, and
exposed to scalar concentrations of the test compounds. Cell survival was evaluated upon 72 h
by the sulphorhodamine B (SRB) or MTT tetrazolium reduction assay and the IC50 value
(drug concentration inhibiting 50% of cell growth) calculated by the ALLFIT program.
FACS analysis
Tumor cells were seeded in 10-cm tissue culture plates, allowed to attach and incubated for 72
h with the test compounds (IC80 dose). After this, cells were harvested with trypsin/EDTA,
rinsed with cold PBS, and fixed in 70% ice-cold ethanol at 4 ˚C. The day of analysis, cells were
rinsed twice with cold PBS, incubated with RNase A (50 KU/ml) for 30 min. at 37˚C, stained
with propidium iodide (PI, 50 μg/mL) and processed on a FACScan flow cytometer (Becton
Dickinson). The CellQuest software (BD Biosciences) was used to acquire data, while cell cycle
analysis was performed using the ModFit software (Verity Software House).
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HDAC’s profiling
The experiments were carried out in RBC facility (http://www.reactionbiology.com/) by using
in triplicate 10 concentrations of each compound starting from 10 μM. The substrate for
HDAC1,2,6, and 10 was Fluorogenic peptide from p53 residues 379–382 (RHKK(Ac)AMC).
The Substrate for HDAC4 was Fluorogenic HDAC Class2a Substrate (Trifluoroacetyllysine)
IC50 values were calculated using the GraphPad Prism 4 program based on a sigmoidal dose-
response equation.
Protein analysis
NCI-H460 cells in logarithmic phase of growth were collected in Dulbecco’s 1x PBS buffer and
lysed in RIPA lysis buffer (50mM Tris-HCl, 150 mM NaCl, 0,5% Na-Deoxycolate, 1% NP-40,
0.15% SDS) containing protease and phosphatase inhibitors and then centrifuged at 12000 rpm
for 10 min at 4 ˚C. The supernatant, containing the total proteins extracts, were transferred in
new vials. The protein concentration was measured by Bradford Protein Assay. Equal amounts
of proteins for each sample were then resolved by SDS-PAGE and loaded on 10–12% polyacrila-
mide gels. The proteins were then transferred on nitrocellulose membranes. Molecular weights
were estimated based upon the relative migration with molecular weight protein markers.
The non-specific binding was blocked by incubation of membranes in TBS-tween (25 mM
Tris, 150 mM NaCl, 0.1% Tween 20) with 5% nonfat dry milk (BIORAD, Milan) for 60 min-
utes. Subsequently, the membrane was incubated overnight with primary antibodies: anti-His-
tone H4 (Millipore, 1:500), anti-acetyl-H4 (Santa Cruz, 1:1000) anti-p21 (Santa Cruz, 1:1000),
anti-acetyl-tubulin (abcam, 1:1000), anti-α-tubulin (Sigma, 1:5000), anti β-actin (Sigma,
1:5000) and anti-Topoisomerase 1 (Santa Cruz, 1:500). After three washes with TBST blots
were incubated with HRP-coniugated secondary anti-mouse and anti-rabbit (Santa Cruz,
1:5000) 1 hour at room temperature. After three washes with TBST the blots were developed
with ECL substrate (GE Healthcare) and chemiluminescence detected by ChemiDoc Imaging
System (Biorad). The optical density of the protein bands detected by western blotting was
normalized on α -tubulin levels and analyzed by ChemiDoc software (Biorad).
Animal model
Female 4–6 weeks old nude mice (CD1 nu/nu) were purchased from Charles River Laborato-
ries (Calco (Lecco) Italy) and kept in polisulfone IVC cages (33.2 x 15 x 13 cm, Tecniplast)
with 75 complete changes of filtered air per hour (HEPA H 14 filter); autoclaved dust-free bed-
ding and mouse house enrichment device (Tecniplast) were used.
Animals were housed under a light-dark cycle, keeping temperature and humidity constant.
Parameters of the animal rooms were assessed as follows: 22 ± 2 ˚C temperature, 55 ± 10% rela-
tive humidity, about 15–20 filtered air changes/hour and 12 hour circadian cycle of artificial light
(7 a.m., 7 p.m.). Mice were fed with a complete irradiated pellet diet (GLP 4RF21, Mucedola) ad
libitum throughout the entire duration of the experiment, and had unrestricted access to drink-
ing water. All animal studies were conducted in accordance with Ethics approval obtained from
the Italian Ministry of Health and all experiments were in accordance with the European guide-
lines for the care and use of laboratory animals. All procedures were performed under deep iso-
flurane anesthesia and at the end of experiments were sacrified by cervical dislocation.
In vivo antitumor activity
Human epithelioid mesothelioma MM473-Luc (luciferase-expressing) cells were cultured in
complete medium, checked with Mycoplasma Detection Kit (Lonza) to exclude mycoplasma
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contamination, counted by trypan blue dye exclusion test to assess cell viability (> 95%), re-
suspended in M199 medium, and orthotopically inoculated intrapleurally (i.pl.) in CD-1 nude
mice (Charles River) at a concentration of 1x106/200μl M199/mouse. Compound 3d was
diluted in 10% 1:1 absolute ethanol-Cremophor solution in saline and was administered i.v. at
45 mg/kg using q4dx3w schedule. Irinotecan was administered iv at 35 mg/kg, using the
schedule q4dx3. Tumor growth was evaluated weekly by using the IVIS Spectrum (PerkinEl-
mer) in vivo technology system, through intraperitoneal injection of D-Luciferin potassium
salt (100μL/10gr, PerkinElmer). After the IP D-luciferin injection, mice were anesthetized in
an oxygen-rich induction chamber with 2% isofluorane, and images were captured 30 minutes
after D-Luciferin injection in order to allow substrate distribution. Tumor volume was mea-
sured as average radiance that is the total flux of photons or radiance (photons/second from
the surface) in each pixel, summed or integrated over the ROI area, in a square centimeter
(cm2) of the tissue. (photons/sec/cm2/sr). The established maximum average radiance was
1x108 photons/sec/cm2/sr, used as humane end-point.
Statistical analysis
Statistical analysis was performed by using U-Test (GraphPad Prism 6). Outliers were removed
by using the Rout test (Q = 10%, GraphPad Prism 6).
Molecular modeling
The ligand molecules were obtained using a systematic conformer search followed by geome-
try optimisation of the lowest energy structure with MOPAC7 (PM3 Method, RMS gradient
0.0100). The DNA-Topoisomerase-I and HDAC-II models were derived from the deposited
X-ray structures (Protein Data Bank entry 1T8I and 5IWG, respectively) as previously
described [3].
Energy minimisations and molecular modeling calculations were performed by using the
GROMACS package [28] and the AMBER-03 [29] force field, a variant of the AMBER-99 [30]
potential in which charges and main-chain torsion potentials have been derived based on QM
+continuum solvent calculations and each amino acid is allowed unique main-chain charges
(nucleic acids have not been modified from AMBER-99).
Molecular docking experiments were performed with Autodock 4.0 [31]. We used the
Lamarckian Genetic Algorithm which combines global search (Genetic Algorithm alone) to
local search (Solis and Wets algorithm) [32]. Ligands and receptors were further processed
using the Autodock Tool Kit (ADT) [33]. Gasteiger–Marsili charges [34] were loaded on the
ligands in ADT and Cornell parameters were used for the phosphorous atoms in the DNA.
Solvation parameters were added to the final structure using the Addsol utility of Autodock.
Each docking consisted of an initial population of 100 randomly placed individuals, a maxi-
mum number of 200 energy evaluations, a mutation rate of 0.02, a crossover rate of 0.80, and
an elitism value of 1. For the local search, the so-called pseudo-Solis and Wets algorithm was
applied using a maximum of 250 iterations per local search. 250 independent docking runs
were carried out for each ligand. The grid maps representing the system in the actual docking
process were calculated with Autogrid. The dimensions of the grids were 80×80×80, with a
spacing of 0.1 Å between the grid points and the center close to the cavity left by the ligand
after its removal. The simpler inter-molecular energy function based on the Weiner force field
in Autodock was used to score the docking results. Results differing by less than 1.0 Å in posi-
tional root-mean-square deviation (rmsd) were clustered together and were represented by the
result with the most favorable free energy of binding. The poses were equilibrated by a 10.0 ns
of partially restrained molecular dynamics simulation using the GROMACS package.
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Results and discussion
Chemistry
We envisaged that the appropriate combination and outdistancing between the CPT scaffold
and a SAHA-like portion could lead to compounds characterized by suitable size and geomet-
rical shape for fitting both enzymes’ binding pockets. In previous papers we reported that
CPT- functionalization at C-7 is highly tolerable. Particularly, we synthesized 7-oxyimino-
methyl derivatives, showing potent in vitro and in vivo activity [25–27, 35, 36]. For this reason,
(E)-7-oxyminomethyl-CPTs were selected for conjugation to a SAHA-like pharmacophore via
a suitable chain. The CPT ring system should act as a surface recognition cap group for HDAC
inhibition, at the same time maintaining the Top1 inhibition activity. To investigate the opti-
mal linker length, we designed a series of compounds containing a SAHA-like HDAC inhibi-
tor connected to the CPT scaffold by linear alkyl chains.
The reaction route to CPT-HDAC hybrid compounds 3a-c is shown in Scheme 1. The com-
pounds were prepared reacting the dimethylacetal of 7-formylcamptothecin (1a) with suitable
hydroxylamines to obtain the oximes 2a-c [3]. The carboxylic acid group was then trans-
formed into a hydroxamic acid by reaction with hydroxylamine hydrochloride (Fig 2).
The CPT derivatives in clinical practice, Topotecan and Irinotecan, have a hydroxy group
at C-10. In order to elucidate the contribution of this group, we prepared the 10-OH substi-
tuted analogue of compound 3b (e.g. compound 3d) starting from 7-formyl-10-hydroxy-CPT
(1b) [27] (Fig 2). Furthermore, we decided to investigate the effect of the replacement of the
hydroxamic acid moiety with a different HDAC Zn-binding group. Accordingly, we prepared
compound 10, carrying a mercaptoacetamide group in place of the hydroxamic acid [37]. The
synthetic route is described in Fig 3. N-Boc protected 6-aminohexanol 4 was reacted with N-
hydroxyphthalimide in Mitsunobu conditions to give compound 5, which was deprotected
and subsequently coupled with S-tritylmercaptoacetic acid [38]. The obtained hydroxylamine
8 was reacted with 7-formylcamptothecin [27] to give the oxime 9, which after removal of trityl
group by TFA, gave mercaptoacetamide 10.
A series of similar compounds, having however the SAHA-like chain attached to the C-10
of CPT via an ether bond, has been recently reported by Oyelere and coworkers [39]. Another
series of 10-O-ether derivatives have been described in a patent [40]. The most active of these
compounds, CY-700, has been prepared by us for comparison (see below).
Molecular modeling studies
DNA-Top1 complexes. Molecular modelling studies were performed to explore the bind-
ing mode for compounds 3a-d and 10 to the DNA-Top1 complex. The compounds are
Fig 2. Synthesis of compounds 3a-d. Reagents and conditions: a) for 2a-c: HClH2NO(CH2)nCOOH, acetic acid, 80 ˚C, 3h; for 2d: HClH2NO
(CH2)nCOOH, EtOH, pyridine, reflux, 4h; 2a: 90%, 2b: 73%, 2c: 70%, 2d:75%; b) for 3a: DCC, NHS, HClNH2OH, rt, 48h, 10%; for 3b-d, WSC, HOBt,
DMF, NH2OHHCl, TEA, rt, 1-8h, 3b: 61%, 3c: 45%, 3d: 73%.
https://doi.org/10.1371/journal.pone.0205018.g002
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properly positioned inside the intercalation binding site, created by conformational changes of
the phosphodiester bond between the +1 (upstream) and -1 (downstream) base pairs of the
uncleaved strand, which effectively ‘‘open” the DNA duplex, with multiple strong π-π stacking
interactions between the aromatic A, B and D rings of the camptothecin and both the -1 (T10-
A113) and +1 (G11-C112) base pairs (Fig 4).
Compounds 3b and 3d show a hydrogen bond between the nitrogen atom N1 of ring B and
R364NH2 residue, which also forms an additional hydrogen bond between R
364NH1 and the
OH group of the lactone ring E of all five compounds (see Table 1). The lactone ring is involved
in other two interactions with the DNA-Top1 target. The first hydrogen bond, common to all
Fig 3. Synthesis of compound 10. Reagents and conditions: a) N-hydroxyphthalimide, PPh3, DIAD, THF, 63%; b)
TFA, CH2Cl2, 94%; c) TrSCH2COOH, EDCI, DMAP, TEA, CH2Cl2, 53%; d) NH2NH2, CH3OH, 83%; e)
7-formylcamptothecin, EtOH, 91%; f) TFA, Et3SiH, CH2Cl2, 80%.
https://doi.org/10.1371/journal.pone.0205018.g003
Fig 4. (Left)—Schematic representation of the proposed top-score binding mode for compound 3d in the
DNA-Topoisomerase-I complex. Topoisomerase-I is represented as Backbone Ribbon colored from blue (N-term) to
red (C-term), while nucleic acids are represented as an arrow along the backbone pointing toward the C3’-end, and
sugar groups and bases as boxes (A in red, C in violet, G in green and T in blue). The 3d ligand and the catalytic
tyrosine (CT) are rendered in CPK (3d in red and CT in blue). (Right)—Hypothetical binding mode for the Top-score
conformation of 3d in complex with DNA-Topoisomerase-I, with the aminoacids side chains relevant to the
discussion rendered in line and the ligands in stick. Hydrogen bonds are shown as green dotted lines.
https://doi.org/10.1371/journal.pone.0205018.g004
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five compounds, still involves the OH group of the lactone ring and D533Oδ2. The other interac-
tion is represented by a bidentate hydrogen bond formed between K532NzH2/3 and the C = O
group of 3a, 3c, 3d and 10, while 3b is able to form a single hydrogen bond with K532NzH2
only. The interaction pattern of the compound 3d within the binding site is completed by a
hydrogen bond between the camptothecin phenolic 10-hydroxy and E356Oε2, an interaction
clearly impossible for the other compounds. Moreover, the phenolic 10-hydroxy of 3d forms a
strong intramolecular hydrogen bond with the carboxyl group of the side chain (1.66Å),
increasing the stability of the complex which is the best among those studied in this paper.
The side chains of the five compounds are located in the rear region of the binding site, rest-
ing on the DNA duplex and forming a series of interactions that contribute to the stability of
the complexes (Table 1). The only interaction common to all the studied compounds is the
hydrogen bond between (-1)A113H62 and the oxygen of the oxime group, that only in 3b forms
a second hydrogen bond with (-1)A113H61. The C = O group of the 3a side chain interact with
K425NzH1, while 3b forms a bidentate bond with both K
425NzH1 and K
425NzH2. The interac-
tion with K425 is absent in 3c-d and 10, where the C = O group is rotated to form a hydrogen
bond with W416Nε1.
The interaction of the hydroxyamic NH group with the target is present only for com-
pounds 3a, 3c and 3d, involving however different residues: 3a with Y426O, 3c with E356Oε2,
3d with K354O. Finally, the interaction pattern of the side chains is completed by the interac-
tions of the hydroxamic OH group with the DNA-topoisomerase-I system, present only in 3b,
3c and 3d, but also in this case with different residues: 3b with (-1)A113N7, (-1)A
114H61 and
K425NzH2, 3c with E
356N and K354O, 3d with E356Oε2.
HDAC-II complexes. The complexes are obtained by molecular docking of 3a-d and 10
using the Class I Rpd3-like protein HDAC2 as a model.
While the 3a-d series shows minor structural modification in the linker length, 10 is rather
different, due to the presence of the SH group, which might change the interactions with the
catalytic zinc ion that is essential for enacting the enzyme. Apart from these differences, all the
ligands enter the binding site in a very similar way, with the functionalized side chain inside
the cavity and the camptothecin system that interacts with the external surface near the
entrance to the cavity (Fig 5).
Table 1. Binding free energies (kcal/mol) and selected distances (in Å) between the five ligands and the residues of the DNA-Top1 system.
Interactions occouring within the binding site
ΔGbinding K
532NzH2 K
532NzH3 D
533Oδ2 R
364NH1 R
364NH2 E
356Oε2 (-1)T
10 (-1)A113 (+1)G11 (+1)C112
3a -9.21 2.66 2.68 2.32 2.43 - - π-π π-π π-π π-π
3b -10.47 - 2.37 2.05 2.61 2.83 - π-π π-π π-π π-π
3c -9.24 2.70 2.82 2.44 2.43 - - π-π π-π π-π π-π
3d -11.82 2.70 2.61 1.64 2.30 2.67 2.95 π-π π-π π-π π-π
10 -9.08 2.85 2.83 2.60 2.32 - - π-π π-π π-π π-π
Interactions involving the rear region of the binding site
K425NzH1 K
425NzH2 Y
426O E356Oε2 E
356N K354O W416Nε1 (-1)A
113N7 (-1)A
113H61 (-1)A
113H62 (-1)A
114H61
3a 2.29 - 1.68 - - - - - - 2.86 -
3b 2.82 1.75 - - - - - 2.18 2.93 2.92 1.89
3c - - - 1.63 1.98 1.56 - - - 2.44 -
3d - - - 2.55 - 2.57 - - - 2.88 -
10 - - - - - - 1.94 - - 2.68 -
Stacking interactions between the aromatic rings of camptothecin and the -1 (T10-A113) and +1 (G11-C112) base pairs are indicated with π-π.
https://doi.org/10.1371/journal.pone.0205018.t001
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As expected, the docking results of 3a-d were very similar and their side chains are highly
superimposed. Their common interactions include a hydrogen bond from the hydroxamic
NH towards G154O and two interaction involving the hydroxamic C = O group; a hydrogen
bond with H183Hδ1 and the chelation of the catalytic Zn
2+ ion (Table 2). The residue Y308 is
directly involved only in the binding of the compounds having the spacer with n = 5 (3b and
3d), through a hydrogen bond involving Y308O and the C = O group of both compounds, and
a further hydrogen bond between Y308O and the hydroxamic OH of the 3d compound alone,
which further stabilizes its conformation. Compound 10 still exhibits the interactions with
G154 and H146, but there is no hydrogen bond with Y308. The loss of the interaction with Y308 is
almost certainly attributable to the non-optimal spacer length, considering that the same effect
is also found in compounds 3a and 3c. Furthermore, unlike 3a-d compounds, in 10 the zinc
ion is complexed by the sulfur atom, which also interacts with rings of H145, H146 and Y308,
forming three Pi-Sulfur interactions.
The portions of 3a-d and 10 interacting with the binding site are delimited by the oxime
group, which in fact lies in all cases at the entrance of the cavity. The camptothecin chain leans
Fig 5. (Left)—Solvent Accessible Surface (SAS) representation of HDAC bond to 3d (in stick). The portions of
molecule interacting with the binding site is delimited by the oxime group, located near the entrance of the cavity.
(Right)—Binding mode of the top-score conformation of 3d to HDAC-II, with the aminoacids side chains relevant to
the discussion rendered in line and the ligand in stick. Hydrogen bonds are shown as green dotted lines.
https://doi.org/10.1371/journal.pone.0205018.g005
Table 2. Binding free energies (kcal/mol) and distances (in Å) between the five ligands and HDAC II residues forming the catalytic binding site.
Interactions occouring within the binding site Interactions involving Camptothecin
ΔGbinding G
154O H146Hε2 Y
308OH Zn2+ D104Oδ1 E
208O Y209N Y209 F210
3a -7.53 2.01 2.57 - 2.86 - - - π-π π-π
3b -7.66 2.03 2.91 1.97 2.53 - - - π-π -
3c -7.36 2.00 2.32 - 2.90 - - - π-π -
3d -7.89 1.90 2.76 1.91 (OH)
2.14 (C = O)
2.74 1.56 1.98 - - -
10 -7.78 2.35 2.51 - 2.54 - - 3.01 - -
Stacking interactions are indicated with π-π.
https://doi.org/10.1371/journal.pone.0205018.t002
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to rest on the outer surface of the receptor to form interactions with residues at the rim of the
pocket. For 3a-c the only observed π-π stacking interactions are with the residue Y209 (3a-c),
while only 3a is able to form a pi-pi stacking with F210, evidently aided by the shorter linker
that forces the camptothecin skeleton to approach the surface. In contrast, compound 10 does
not show π-π stacking interactions with residues at the rim of the pocket, but is still anchored
to the target surface by a hydrogen bond between the camptothecin carbonyl oxigen in 17 and
Y209N.
In compound 3d, the presence of the 10-hydroxy group and the optimal spacer length
makes it once again unique among the studied compounds. These two structural features pro-
vide 3d with the possibility of tightly interacting with the external surface through two strong
hydrogen bonds, one between the OH of the lactone E ring and D104Oδ1 and the other between
the phenolic 10-hydroxy and E208O.
Finally, compound 3d was superimposed to the reference ligands CPT and SAHA in the
catalytic sites of Top1 and HDAC II, respectively (Fig 6A and 6B). Fig 6A shows the superim-
position of 3d and CPT in the catalytic site of Top1. The two conformations are almost per-
fectly superimposed, with the exception of the D-E rings, which in 3d move close to K532 and
D533 to obtain a better interaction. The overlap of 3d and SAHA within the HDAC-II catalytic
site is reported in Fig 6B. Although the functional groups are different, the two molecules
behave similarly within the cavity, both interacting with the same residues and chelating the
Zn++ ion. The two structures diverge as one moves away from the centre of the cavity, as a
result of the different interaction with the surface of the enzyme. This behaviour can be
explained considering the different dimensions and properties of the 3d and SAHA terminal
groups.
Overall, the results obtained showed that hybrids with a 5/6 carbon chain are capable of
forming stable complexes with both HDAC and Top1. Compound 3d has the most favourable
interactions and its promising binding mode provides a computational validation to our plan
to combine the CPT and SAHA-like motifs in a single molecule.
Biological activity evaluation
The antiproliferative activity was evaluated on a series of human tumor cell lines (NCI-H460:
non small cell lung cancer; CAPAN 1: human pancreatic ductal adenocarcinoma; A431:
Fig 6. (A)–Superimposition of the 3d (in red) and CPT (blue) structures in the catalytic site of Top1. (B)—Overlap of
3d (red) and SAHA (blue) within the HDAC-II catalytic site.
https://doi.org/10.1371/journal.pone.0205018.g006
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human epidermoid carcinoma; HeLa: human epithelioid cervix carcinoma; HT29: human
colon adenocarcinoma; DU145: human prostate carcinoma; HepG2: human liver hepatocellu-
lar carcinoma; A2780: human ovarian carcinoma; A2780-Dox: human doxorubicin-resistant
ovarian carcinoma). The activity was assessed after 72 h with the SRB assay.
Compounds 3a-c, having different linker length, showed significant antiproliferative activ-
ity, suggesting that the chain was flexible enough to effectively position the molecule within
the enzymes’ active sites. Compound 3d, the 10-hydroxy substituted derivative of 3b, showed a
very potent antiproliferative activity as well. In fact, it displayed a cytotoxic activity in the
nanomolar range (0.03 μM< IC50 < 0.4 μM), while SAHA (IC50 > 0.9 μM), Irinotecan (IC50
> 1.5 μM), and the reference compound dual inhibitor CY-700 (0.3 μM< IC50 < 3.3 μM)
were all less effective (Table 3). Compound 10, carrying a Zn-binding group different from the
hydroxamic acid, maintained a significant antiproliferative activity.
Compounds 3b and 3d were selected for a deeper characterization of their target modula-
tion and specificity.
Initially, a comparative study on different purified HDAC isoforms was carried out
(Table 4).
Both compounds showed a significant activity against four purified HDAC isoforms, repre-
sentative of class I (HDAC 1, 2) and Class IIb (HDAC 6, 10) HDACs, with IC50 comparable to
those of the reference compound Trichostatin A, without substantial selectivity. Conversely,
both compounds were inactive against HDAC 4 (representative of Class IIa HDACs)
(Table 4). This result was not unexpected, as it is well known that SAHA inhibits class IIa
enzymes at concentrations that are not clinically significant [41].
Table 3. Human tumor cell lines exposed to Top1, HDAC, and dual Top1/HDAC inhibitors.
NCI-H460 Capan 1 A431 HeLa HT29 DU145 HepG2 A2780 A2780-Dx RI
Cpda IC50 ± SD (μM)
Irinotecan 2.4 ± 0.1 1.5 ± 0.1 4.1 ± 0.1 5.8± 0.6 4.8 ± 0.4 2.8 ± 0.07 4.0 ± 0.8 3.8 ± 0.5 20.1± 2.9 5.3
SAHA 5.0 ± 0.2 1.8 ± 0.2 3.5 ± 0.1 2.7 ± 0.2 2.2 ± 0.3 0.87 ± 0.03 1.54 ± 0.1 2.1 ± 0.2 3.3 ± 0.6 1.6
CY700 0.36 ± 0.02 0.96±0.08 0.79± 0.1 3.3± 0.9 1.2 ± 0.2 0.87±0.04 1.5 ± 0.4 2.5 ± 0.3 5.9 ± 1.0 2.4
3a 0.36 ± 0.10 0.05± 0.006 n.e. n.e. n.e. n.e. n.e. n.e. n.e.
3b 0.023±0.004 0.006±0.0007 0.004±0.001 0.16±0.04 n.e. n.e. n.e. 0.008±0.002 0.27±0.070 31.7
3c 0.198±0.18 0.043± 0.003 0.026±0.001 2.4 ± 0.5 0.045±0.01 0.029±0.001 0.68±0.2 0.038±0.008 0.065±0.01 1.7
3d 0.27 ± 0.02 0.035 ± 0.002 0.14 ± 0.02 0.18±0.05 0.39±0.1 0.07±0.003 0.11±0.03 0.27 ± 0.08 1.8 ± 0.4 6.6
10 0.1 ± 0.01 n.e. n.e. n.e. n.e. n.e. n.e. 0.21 ± 0.05 0.35 ± 0.1 1.7
aHuman tumor cell lines were treated with various Top1, HDAC, and dual Top1/HDAC inhibitors and the anti-proliferative activity assessed after 72 h with the SRB
assay. RI = Resistance Index. Ne = not evaluated.
https://doi.org/10.1371/journal.pone.0205018.t003
Table 4. Inhibition of HDAC isoforms by compounds 3b, 3d.
Compounda HDAC1 HDAC2 HDAC4 HDAC6 HDAC10
3d 5,26E-08 9,33E-08 n.a 1,56E-09 2,24E-07
3b 4,30E-08 7,62E-08 n.a. 3,87E-09 9,99E-08
Trichostatin A 1,244E-08 2,36E-08 - 2,09E-09 3,20E-08
TMP269 - - - - 3.53E-07 - - - -
aIC50 values were calculated using the GraphPad Prism 4 program based on a sigmoidal dose-response equation.
n.a. = not active. Trichostatin A and TMP269 were used as reference standards
https://doi.org/10.1371/journal.pone.0205018.t004
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Subsequent analyses were conducted to verify whether 3b and 3d effectively targeted
HDACs and Top1. To explore the HDAC inhibitory activity of the selected compounds,
NCI-H460 cells were exposed to 3b and 3d (at different concentrations: 0.125, 0.2, 0.5 μM)
and to the reference compounds SN38 (the active metabolite of Irinotecan) and SAHA (0.05
and 5 μM, respectively, corresponding approximately to their own IC80). The accumulation of
both acetylated histone H4 and acetylated tubulin was investigated (Fig 7). Compound 3d,
similarly to SAHA, showed the characteristics of a Pan-HDAC inhibitor, as revealed by H4
and tubulin acetylation in a dose dependent manner. Compound 3b, at a concentration corre-
sponding to its IC80 (0.5 μM), showed to be less potent than 3d on both targets, particularly on
H4 (Fig 7).
Following on from these results, 3d was further investigated to assess its ability to inhibit
Top1. Interestingly, the compound drastically reduced the expression of Top1 (comparable to
SN38) (Fig 8A). This finding is consistent with recent literature, where there is evidence that
treatment with topoisomerase inhibitors significantly decreases the Top I expression [42]. In
addition, 3d induced p53 activation (Fig 8B) and DNA damage at a dose corresponding to its
IC80, confirmed by H2A.X induction (Fig 8A). Interestingly, SN38 and SAHA at equivalent
doses appeared less effective in p53 up-regulation and completely ineffective in H2A.X induc-
tion (Fig 8A and 8B), thus suggesting that the 3d dual targeting activity cooperates in the DNA
damage induction.
Moreover, P16 and CycD1 were down and up-regulated, respectively, by SAHA, while 3d
and SN38 didn’t show any effect. Interestingly, SAHA-induced block of G2/M progression
observed in our experiment (see below) and its induction of p21, p53 and Cyclin D1 suggest
an effect on senescence pathways activation, as recently reported [43].
Furthermore, similarly to SAHA, 3d activated the expression of p21, probably as a conse-
quence of its HDAC inhibitory activity (Fig 8). Taken together, these results suggest that 3d
possesses a dual-inhibitor characteristic, acting at cellular level both as HDAC and Top1
inhibitor.
Fig 7. Effects of compounds 3b, 3d, SN38 and SAHA (reference compounds) on acetylation of tubulin and histone
H4 in NCI-H460 cells. Cells were treated for 24 h with SN38 (0.05 μM), SAHA (5 μM), 3b and 3d (0.125–0.2–0.5 μM).
Cells were lysed in 0.5% NP-40 and 40 μg of total proteins were loaded on NuPAGE 4–12% (Invitrogen), transferred to
a nitrocellulose paper and probed with specific antibodies. Acetylated Histone H4 (Ac-H4); Histone H4; Acetylated
Tubulin (Ac-H4); Tubulin.
https://doi.org/10.1371/journal.pone.0205018.g007
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To assess the antitumor potential of compound 3d, a large screening on hematologic cancer
cell lines was carried out (Tables 5 and 6). The compound showed a cytotoxic potency mostly
in the nanomolar range (0.006 μM< IC50 < 4 μM), superior to SAHA (0.6 μM< IC50 <
9 μM), and Irinotecan (IC50 > 10 μM) in most cell lines. Interestingly, 3d showed an activity
superior to that of CY-700 (0.3 μM< IC50 < 10 μM), the most active compound described by
Chen [40], taken as a reference standard of dual CPT-HDAC inhibitors. These data confirm
the correctness of the choice of linking the HDAC-active chain to the position 7 of
camptothecin.
Lastly, we tested 3d against a series of primary malignant pleural mesothelioma (MPM) cell
lines (from our cell bank collection).
Fig 8. Effects of compound 3d, SN38 and SAHA (reference compounds) on Top1, H2A.X, p21 (A), CycD1, p16,
p53 (B) in NCI-H460 cells. H460 cells were treated for 24 h with SAHA (5 μM), SN38 (0.05 μM), and 3d (0.125–0.2–
0.5μM). Cells were lysed in 0.5% NP-40 and 40 μg of total proteins were loaded on NuPAGE 4–12% (Invitrogen),
transferred to a nitrocellulose paper and probed with specific antibodies.
https://doi.org/10.1371/journal.pone.0205018.g008
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We compared 3d to drugs in clinical use for the treatment of MPM, such as Cisplatin, and
drugs such as Irinotecan, SAHA, Gefitinib, 5-FU, which failed to increase the survival of MPM
patients when investigated in clinical trials [44].
Gratifyingly, 3d showed a potent antiproliferative effect, with IC50 ranging from 0.05 to
11 μM, which was much higher than SAHA (4 μM< IC50 < 12 μM) and Irinotecan (IC50 >
7 μM). Moreover, 3d resulted more effective than Gefitinib (14 μM< IC50 < 38 μM), cisplatin
(1.2 μM< IC50 < 8.0 μM), and 5-FU (18 μM< IC50 < 200 μM), as well (Table 7). These
results are remarkable, considering that mesothelioma still remains an incurable cancer, and
new therapeutic approaches against the disease are urgently needed [45].
Compound 3d was also tested, comparing it with Irinotecan and SAHA, on NCI-H460
NSCLC cell line to assess the effect on cell cycle progression and induction of apoptosis. FACS
analysis revealed a comparable effect of 3d and Irinotecan on cell cycle distribution, with a
steady block of treated-cells in the S phase, while SAHA preferably arrested cells in G2/M.
Interestingly, 3d also had cytotoxic activity, with induction of apoptosis (sub-G0/1 population)
that was lacking in cells treated with Irinotecan and SAHA (Table 8).
The efficacy of the new dual inhibitor 3d was evaluated on human mesothelioma primary
cell line MM473-Luc orthotopically xenografted in CD-1 nude mice. This cell line was stably
transfected with luciferase and was suited for the observation of tumor growth by
Table 6. Human myeloma, leukemia and lymphoma cell lines exposed to 3d and SAHA.
Cell line SAHA 3d
IC50 ± SD (μM)
K 562 1.53 ± 0.4 0.94 ± 0.2
ARH-77 3.9 ± 0.5 0.21 ± 0.06
THP1 3.9 ± 1.4 0.22 ± 0.09
MV4-11 3.84 ± 0.8 2.73 ± 0.3
Jurkat-cp 1.99 ± 0.2 0.23 ± 0.05
U937 1.62 ± 0.3 0.18 ± 0.05
RAJI 1.73 ± 0.6 0.077 ± 0.02
RAMOS 3.9 ± 0.7 0.99 ± 0.1
REC-1 0.94 ± 0.2 0.18 ± 0.04
Z-138 0.7 ± 0.1 0.006 ± 0.001
RPMI-8226 1.98 ± 0.5 4.1 ± 1.4
H929 0.56 ± 0.07 1.1 ± 0.4
Human hematologic cancer cells were exposed to 3d and SAHA and the anti-proliferative activity assessed upon 72h
with the MTT assay.
https://doi.org/10.1371/journal.pone.0205018.t006
Table 5. Human lymphoma and leukemia cell lines exposed to 3d and Top1, HDAC, and dual Top1/HDAC inhibitor CY700.
Cpd MINO MAVER-2 JECO-1 U-2932 OCI-LY3 L-428 KM-H2 DG-75 NB4
IC50 ± SD (μM)
3d 0.031±0.01 0.012±0.001 0.023±0.006 0.044±0.01 0.018±0.005 0.43±0.07 0.39±0.1 1.9±0.2 n.e.
Irinotecan >10(36%) 0.74 ± 0.1 >10 (48%) 4.4 ± 0.8 > 10 (0%) >10(0%) >10(12%) >10(0%) 1.0±0.3
CY700 0.37± 0.1 0.4 ± 0.08 1.0 ± 0.4 0.9 ± 0.3 0.34±0.04 1.7 ± 0.2 1.5 ± 0.5 >10(18%) 0.24±0.06
SAHA 1.1 ± 0.3 5.4 ± 1.2 2.6 ± 0.7 1.1 ± 0.2 0.99 ± 0.3 2.3± 0.5 1.2± 0.2 2.1 ± 0.2 3.3± 0.6
Human hematologic cancer cells were exposed to various Top1, HDAC, and dual Top1/HDAC inhibitors and the anti-proliferative activity assessed after 72 h with the
MTT assay. Ne = not evaluated.
https://doi.org/10.1371/journal.pone.0205018.t005
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chemoluminescence analysis. After tumor cells injection and with tumors in the growth phase
(day 15), mice were intravenously treated with 3d (45 mg/kg, q4dx3w), Irinotecan (35 mg/kg,
q4dx3) or vehicle as negative control (treatments ended at day 32). The tumor volume was
measured as BLI signal and expressed as average radiance.
The molecule administered had a strong antitumor activity as shown in Figs 9 and 10.
Moreover, the tumor chemiluminescence in animals treated with 3d indicated that the com-
pound acts by both reducing the tumor growth progression and, in some cases, by reducing
Table 7. Human primary mesothelioma cell lines exposed to 3d and reference antitumor drugs.
Cpd EPITHELIOID BIPHASIC SARCOMATOID
IC50 ± SD (μM)
MM288 MM317 MM404 MM473 MM481 MM487 MM491 MM432 MM472
3d 0.48±0.1 0.85±0.2 1.4 ±0.3 2.1±0.5 11.7±1.2 0.2±0.05 0.87±0.3 0.16±0.03 0.048±0.01
Irinotecan 14.9±2.0 7.0 ± 1.0 9.4 ± 0.7 10.0±2.0
SAHA 3.8 ±0.2 11.2±0.9 8.8± 1.2 8.5± 0.4 11.5±0.4 7.4 ± 0.4 10.7±0.4 6.9 ± 1.0 4.6 ± 0.8
Gefitinib 38.7±1.4 26.1±2.9 28.4±2.4 18.4±0.7 31.2±1.0 15.0±0.5 14.0±0.7 17.1 ± 1.0 19.1 ± 0.5
Cisplatin 8.1 ± 0.3 4.2 ± 0.6 2.4 ± 0.5 2.4 ± 0.2 7.0 ± 1.5 3.0 ± 0.5 6.5 ± 0.9 5.0 ± 0.8 1.26 ± 0.1
5-FU >200(35%) 17.9±3.1 52.2±8.7 35.2±8.4 27.4±2.2 >200(48%) 44.0±10.3 >200(34%) 40. ± 10.5
Human primary mesothelioma cells were exposed to 3d and different anti-tumor compounds. Anti-proliferative activity was assessed upon 72 h with the SBR assay.
https://doi.org/10.1371/journal.pone.0205018.t007
Table 8. Flow cytometric evaluation of human NCI- H460 NSCLC cells exposed to 3d and reference antitumor
drugs.
NCI-H460a G0/1 (%) S (%) G2/M (%) Sub-G0/1 (%)
Ctr 71.0 23.0 5.9 2.4
3d 12.1 76.0 11.9 15.2
Irinotecan 7.9 89.0 3.2 2.7
SAHA 65.2 11.7 23.1 1.8
aTumor cells were exposed for 72 h to 3d and reference anti-tumor drugs (at their own IC80 dose), stained with PI,
and processed on a FACScan flow cytometer. The CellQuest software was used to acquire data and assess the sub-G0/
1 population, while cell cycle analysis was performed with the ModFit software.
https://doi.org/10.1371/journal.pone.0205018.t008
Fig 9. Efficacy of 3d in an orthotopic xenograft model of human epithelioid mesothelioma. Bioluminescence signal
from mice injected with MM473 expressing luciferase at day 15 (first treatments) and day 40 (8 days after the last
treatment).
https://doi.org/10.1371/journal.pone.0205018.g009
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the tumor size until the disappearance of the bioluminescent signal (8 days after the end of
treatments) (Figs 9 and 10). Conversely, Irinotecan had only a marginal antitumor effect (not
significant, p>0.5) when administered at 35 mg/kg. Interestingly, the antitumor activity was
observed at doses that appear well tolerated (no reduction in body weight was observed, data
not shown).
Conclusion
Synergistic effects have been reported on the use of HDAC and topoisomerase I inhibitors as a
co-treatment on various cancer cells. In this study, new hydroxamic acid derivatives of camp-
tothecin were evaluated as dual-action CPT-HDAC inhibitors. In particular, compound 3d
displayed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar
range, on a series of human solid tumor, hematologic, and mesothelioma cell lines. The new
hybrid molecule showed a potency superior to both HDAC inhibitor SAHA and Top1 inhibi-
tor Irinotecan, increased antitumor activity and very high tolerability in in vivo human tumor
models with respect to SAHA and Topotecan.
In molecular modelling studies, compound 3d showed the most favourable interactions
and its promising binding mode provided structural support to the molecular design and
development of analogues. Overall, the docking interaction profiles of synthesized compounds
were in accordance with the biological results, especially for selected compound 3d, which was
found to have significantly better interactions with both target proteins. This finding can be
explained considering the simultaneous presence in 3d of the phenolic -OH on ring A of
camptothecin (10-hydroxy) and the right length of the linker (n = 5). These two structural fea-
tures represent the driving force that makes 3d a better ligand for both the DNA-Top1 binary
complex and the HDAC-II active site.
The single dual-function molecule not only attacks the cancer cells from two distinct path-
ways simultaneously but also improves drug efficacy of the conventional CPT without increas-
ing its dose-limiting toxicity. Therefore, it can be used for treating tumors susceptible to
camptothecin drugs and/or to HDAC inhibitors, showing at the same time a good tolerability
and low toxicity.
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